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ABSTRACT
Neurospheres derived from glioblastoma (GBM) and
other solid malignancies contain neoplastic stem-like cells
that efficiently propagate tumor growth and resist cyto-
toxic therapeutics. The primary objective of this study
was to use histone-modifying agents to elucidate mecha-
nisms by which the phenotype and tumor-promoting
capacity of GBM-derived neoplastic stem-like cells are
regulated. Using established GBM-derived neurosphere
lines and low passage primary GBM-derived neuro-
spheres, we show that histone deacetylase (HDAC) inhibi-
tors inhibit growth, induce differentiation, and induce
apoptosis of neoplastic neurosphere cells. A specific gene
product induced by HDAC inhibition, Delta/Notch-like
epidermal growth factor-related receptor (DNER), inhib-
ited the growth of GBM-derived neurospheres, induced
their differentiation in vivo and in vitro, and inhibited
their engraftment and growth as tumor xenografts. The
differentiating and tumor suppressive effects of DNER, a
noncanonical Notch ligand, contrast with the previously
established tumor-promoting effects of canonical Notch
signaling in brain cancer stem-like cells. Our findings are
the first to implicate noncanonical Notch signaling in the
regulation of neoplastic stem-like cells and suggest novel
neoplastic stem cell targeting treatment strategies for
GBM and potentially other solid malignancies. STEM
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INTRODUCTION
During the past decade, there has been a re-emergence of the
concept that cancers harbor small populations of malignant
stem-like cells that sustain tumor growth and recurrence.
These ‘‘neoplastic stem cells’’ [1], which share the defining
phenotypic characteristics of self-renewal, multipotential dif-
ferentiation at least equivalent to that in the primary tumor,
and long-term tumor propagation [2, 3], have been identified
in leukemia and multiple myeloma [4–6], and more recently
in solid tumors, including mammary carcinoma [7] and pri-
mary brain tumors [3, 8–10]. The potential role for multipo-
tent stem/progenitor cells in brain cancer initiation is sup-
ported by the fact that directing oncogenic growth signals to
nestin-positive or glial fibrillary acidic protein (GFAP)þ neu-
ral progenitor cells in rodents causes high-grade glioma [11,
12]. Independent of the potential contribution of stem cells to
tumor initiation, a current view is that neoplastic cells with
stem-like properties underpin the maintenance and therapeutic
resistance of malignant glioma. This concept is based on the
identification of tumor cells that express stem cell markers
(CD133, aldehyde dehydrogenase [ALDH], side-population),
grow in vitro as neurospheres under serum-free conditions
that support the growth of normal neural stem cells, resist ion-
izing radiation, and propagate tumor xenografts with high
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efficiency [3, 8–10, 13–15]. Understanding the molecular
mechanisms that regulate the stem-like tumorigenic phenotype
of these cells will improve our understanding of malignant
brain tumors and lead to novel stem cell-targeting therapeutics
[16–18].
Epigenetic mechanisms of gene expression regulation play
an important role in the oncogenic phenotype and in the
maintenance/differentiation of normal neural stem cells [19–
21]. One of the most prominent of these epigenetic mecha-
nisms involves chromosome modification by histone acetyla-
tion, which is determined by the opposing actions of histone
acetyltransferases and histone deacetylases (HDACs) [22, 23].
Acetylation of lysine residues in the histone tail promotes
gene transcription by relaxing the chromosome, allowing the
transcriptional machinery to access DNA. Conversely, histone
deacetylation often followed by methylation compacts chro-
matin and represses gene expression [24]. Neural stem cell
proliferation can be regulated by histone acetylation/deacety-
lation via numerous molecular mechanisms, including cell
cycle regulation, apoptosis control, and the activation of dif-
ferentiation [20, 25–27]. Oncogenesis is associated with a
relative decrease in histone acetylation, leading to the tran-
scriptional repression of tumor suppressor genes, a common
event contributing to tumor formation [28].
In light of the accelerating interface between brain cancer
and neural stem cells and the sensitivity of both to histone
modification, we used HDAC inhibitors (HDACIs) to explore
the biological and molecular basis of the glioblastoma (GBM)
stem-like cell phenotype. HDACIs were found to inhibit the
growth of GBM-derived neurospheres, induce neurosphere
cell apoptosis, and deplete neurosphere cultures of cells
expressing stem cell markers. HDACIs induced GBM-derived
neurosphere cell differentiation and inhibited the ability of
neurosphere cells to propagate tumor xenografts. Biological
responses to HDAC inhibition were mediated, in part, by
upregulating the noncanonical Notch ligand Delta/Notch-like
epidermal growth factor (EGF)-related receptor (DNER),
which was found to inhibit GBM-derived neurosphere forma-
tion, induce neurosphere cell differentiation, and inhibit the
growth of neurosphere-derived tumor xenografts. This is the
first evidence that the DNER signaling pathway has differenti-
ating and tumor-suppressing actions on glioma-derived stem-
like cells.
EXPERIMENTAL PROCEDURES
Reagents
All reagents were purchased from Sigma Chemical Co. (St.
Louis, http://www.sigmaaldrich.com) unless stated otherwise.
Trichostatin A (TSA) and MS-275 (N-(2-aminophenyl)-4-[N-
(3-pyridineyl-methoxycarbonyl)aminomethyl]-benzamide) were
prepared as stock solutions in dimethylsulfoxide (DMSO). In all
the experiments, the final DMSO concentration was<0.1%.
Cell Culture
The human GBM-derived neurosphere lines HSR-GBM1A
(20913), HSR-GBM 1B (10627), and 050,509 were derived
by Vescovi and colleagues and maintained in serum-free me-
dium supplemented with EGF and fibroblast growth factor
(neurosphere medium), as previously described [10, 29, 30].
The DM140207 neurosphere line was derived from a GBM at
the University of Freiburg and primary JHH225 neurospheres
were derived from a malignant glioma at Johns Hopkins Uni-
versity (Baltimore, Maryland) using the same methods
and culture conditions. JHH225 neurospheres were used at
passage 9. All human materials were obtained and used
in compliance with the Johns Hopkins institutional review
board.
Cell Growth and Clonogenic Assays
Cell growth was measured by colorimetric assay using 3-(4,5-
dimethylthiazol-2-yl)-5(3-carboxymethonyphenol)-2-(4-sulfo-
phenyl)-2H-tetrazolium (MTS) (Promega, Madison, WI,
http://www.promega.com). Briefly, 50 ll of a stock solution
of MTS was added to each cell culture well to achieve a final
concentration of 333 lg/ml. The reduction in MTS, reflecting
the number of viable cells per well, was measured after 3
hours by quantifying the absorbance at 490 nm.
For soft agar clonogenic assays, agarose (1%; Invitrogen,
Carlsbad, CA, http://www.invitrogen.com) in Dulbecco’s
modified Eagle’s medium was cast on the bottom of plastic
six-well plates. Dissociated neurosphere cells were suspended
in neurosphere culture medium containing 0.5% agarose equi-
librated at 37C and plated at 5  103 cells per well above a
bottom layer of 1% agarose. Cells were incubated in a
humidified incubator containing 5% CO2 and 95% air at 37
C
for 2 hours and then the medium was replaced with that con-
taining 200 nM TSA. Cultures were incubated in 5% CO2
and 95% air at 37C for 14 days and then colony formation
was scored by measuring the number of spheres 100 lm in
diameter in nine random microscopic fields per well.
Transient Transfection
Neurosphere cells were transfected with hemagglutinin-tagged
full-length DNER expression plasmid, a kind gift of Mineko
Kengaku (RIKEN Brain Science Institute, Saitama, Japan)
[31], using Amaxa nucleofection technology (Amaxa, Koeln,
Germany, http://www.amaxa.com). Cells were suspended in
Amaxa Primary Neurons Kit solution, according to Amaxa
guidelines. Briefly, a 100-ll suspension of 2-5  106 cells
was mixed with 3 lg plasmid DNA and subjected to nucleo-
fection using an Amaxa Nucleofector apparatus. Cells were
then immediately transferred into six- or 12-well tissue cul-
ture plates containing neurosphere culture medium prewarmed
to 37C. Cells were cultured for an additional 72 hours
before experimental analyses. Transfection efficiencies were
routinely 60% as measured by parallel transfection with a
green fluorescent protein reporter under identical conditions.
Immunoblot Analysis
SDS-PAGE was performed on 30 lg of cellular protein per
lane using 4%–20% gradient Tris-glycine gels according to
the method of Towbin et al. with some modifications [32,
33]. Proteins were electrophoretically transferred to nitrocellu-
lose membranes (GE Healthcare, San Diego, http://www.ge-
healthcare.com). Membranes, except for those to be probed
with anti-DNER, were incubated for 1 hour in Odyssey Licor
Blocking Buffer (LI-COR Biosciences, Lincoln, NE, http://
www.licor.com) at room temperature and then overnight
with anti-glyceraldehyde-3-phosphate dehydrogenase (1:7,500;
Santa Cruz Biotechnology Inc., Santa Cruz, CA, http://
www.scbt.com) or anti-b-actin (1:6,000; Sigma), anti-Deltex-1
(1:300; Santa Cruz Biotechnology), anti-GFAP (1:500; Dako,
Carpinteria, CA, http://www.dakousa.com), anti-TuJ1
(1:1,000; Millipore Corporation, Billerica, MA, http://
www.millipore.com), anti-histone-4 (1:1,500; Upstate, Char-
lottesville, VA, http://www.upstate.com), or anti-scetyl-his-
tone-4 (1:1,000; Upstate) at 4C in Odyssey Blocking Buffer
(LI-COR Biosciences). After rinsing, membranes were incu-
bated with IRDye secondary antibodies (1:15,000; LI-COR
Biosciences) and protein expression changes were quantified
by dual wavelength immunofluorescence Odyssey Infrared
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Imaging System (LI-COR Biosciences) scanning of the mem-
branes. Immunoblots probed with anti-DNER (1:500; Abnova
Corporation, Taipei City, Taiwan, http://www.abnova.com)
utilized peroxidase-conjugated secondary antibodies, essen-
tially as previous described [34].
Quantitative Real-Time Polymerase Chain Reaction
Total cellular RNA was extracted using the RNeasy Mini kit
(Qiagen, Inc., Chatsworth, CA, http://www1.qiagen.com) and
purified using RNeasy columns according to the manufac-
turer’s instructions. The purity and amount of total RNA were
spectrophotometrically estimated by measuring absorbance at
260 nm and 280 nm. The integrity of rRNA was checked
using agarose gel electrophoresis. Total RNA (1 lg) was
reverse-transcribed (RT) using the oligo(dT)12-18 primer and
Superscript II (Invitrogen) according to the manufacturer’s in-
structions. DNER primer sequences were: 50-CTCCATTTCT
GCATGGGTCT-30 and 50-GAGGAAACCTTGCCAAAACA-
30. MAG primer sequences were: 50-AGCCCCTACCCCAAG
AACTA-30 and 50GACGATATCCAGGACGCTGT-30. HES1
primer sequences were 50-AGCGGGCGCAGATGAC-30 and
50-CGTTCATGCACTCGCTGAA-3. Quantitative real-time
polymerase chain reaction (PCR) was performed with an
Applied Biosystems Prism 7900 HT Sequence Detection Sys-
tem using SYBR Green PCR Master Mix (Applied Biosys-
tems, Foster City, CA, http://www.appliedbiosystems.com).
The thermal cycling conditions were as follows: hold for 10
minutes at 95C, followed by three-step PCR for 40 cycles of
Figure 1. Growth inhibition of GBM-derived neurospheres by HDAC inhibitors. (A): GBM-derived neurosphere lines 20913 and 10627 were
incubated with TSA (200 nM) or MS-275 (4 nM) for 6 days. Neurosphere cell growth was decreased 80% by HDAC inhibition. (B): GBM-
derived neurospheres were cultured continuously for 14 days in neurosphere medium either with buffer only (Con) or with TSA (200 nM) or
MS-275 (4 lM). Alternatively, neurospheres were treated transiently with TSA (or MS-275) for only 3 days and then transferred to drug-free
neurosphere medium for 11 additional days. Neurospheres were then immobilized in agar and the number of neurospheres measuring >100 lm
diameter per low powered microscopic field was counted by computer-assisted morphometry. Neurospheres treated with either TSA or MS-275
for either 3 days or 14 days differed statistically significantly from controls. **p < .01. (C): Shown are representative agar plates (3.5 cm diame-
ter) and 4 microscopic fields (bar ¼ 100 lm) of neurospheres treated with TSA for 14 days as described in (B). Data are shown as the mean 
standard error of the mean. Abbreviations: Con, control; GBM, glioblastoma; HDAC, histone deacetylase; TSA, trichostatin A.
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95C for 15 seconds, 55C for 25 seconds, and 72C for 30
seconds. Samples were amplified in triplicate and data were
analyzed using the Applied Biosystems Prism Sequencer
Detection Software Version 2.3 (Applied Biosystems). Human
18S rRNA was amplified as an endogenous control. Standard
curves were prepared for each mRNA and 18S rRNA for
each amplification to normalize relative gene expression to
the 18S rRNA control.
Gene Expression Knockdown
Predesigned small interfering (si)RNA for human DNER was
purchased from Ambion (ID 125934; Ambion, Austin, TX,
http://www.ambion.com). The resulting double-stranded
siRNA (50 nM) was transfected into cultured cells using
siPort Lipid transfection agent (Ambion). Neurosphere cells
were plated in duplicate in a six-well plate (105 cells per
well) format for RNA analysis and in 48-well plates (1.5 
104 cells per well) for growth assays. For each transfection,
32 ll siPort transfection reagent was mixed with 1.1 ml Opti-
mum Medium (Gibco, Grand Island, NY, http://www.invitro-
gen.com) and incubated at room temperature for 20 minutes.
Three microliters of 20 lM negative control siRNA (Silencer
Negative Control #1 siRNA; Ambion) or DNER siRNA solu-
tion was added to the mixture, which was incubated at room
temperature for another 20 minutes. The mixture was then
added to cell medium and incubated for 48 hours prior to
MTS assay or protein extraction. The silencing effect of the
siRNA construct on DNER expression was confirmed by im-
munoblot analysis. The SiDNER sequence one (SiDNER.1)
sense siRNA strand was 50-GUGUGACCCCCCUUCAGGCtt-
30 and the antisense siRNA strand was 30-ttCACACUGGGG
GGAAGUCCG-50; the SiDNER.2 sense siRNA strand was 50-
GCAGUACGUGGGUACUUUCtt-30 and antisense siRNA
strand was 30-ctCGUCAUGCACCCAUGAAAG-50. The SiDe-
ltex-1.1 sense siRNA strand was 50-GGAUGUGGUUCGAAG
AUACtt-30 and the antisense siRNA strand was 30-ctCCUAC
ACCAAGCUUCUAUG-50; the SiDeltex-1.2 sense siRNA
strand was 50-GCACCUUAAAAAGAGUAAGtt-30 and the
antisense siRNA strand was 30-ttCGUGGAAUUUUUCUCA
UUC-50.
Tumor Xenografts
Female 4- to 6-week-old athymic nude mice were injected
s.c. in the flank with 5  106 viable cells in 0.1 ml of phos-
phate-buffered saline (PBS). When tumors reached 50 mm3,
the mice were randomly divided into groups and treated with
TSA (500 lg/kg in 0.2 ml PBS) or with solvent only as a
control, i.p. daily as previously described [35]. Tumor sizes
Figure 2. HDAC inhibition depletes GBM-derived neurospheres of cells expressing stem cell markers. GBM-derived neurosphere lines were
passaged into neurosphere medium containing buffer only (Con) or either TSA (200 nM) or MS-275 (4 lM) and then cultured for an additional
3 days. Neurosphere cells were then dissociated and subjected to flow cytometry to detect ALDH-expressing cells (A and B) and CD133-express-
ing cells (C). (D): Neurospheres were cultured in the presence of buffer only (control) or TSA as described above. Neurospheres that formed
were collected by cytospin and subjected to immunofluorescence for CD133 and nestin. TSA depleted neurospheres of ALDH- and CD133-
expressing cells. Bar ¼ 20 lm. Data are shown as the mean  standard error of the mean (A–C). **p < .01. Abbreviations: ALDH, aldehyde de-
hydrogenase; Con, control; GBM, glioblastoma; HDAC, histone deacetylase; TSA, trichostatin A.
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were determined weekly by measuring two dimensions—
length (a) and width (b)—and volume (V) was estimated
using the formula V ¼ ab2/2 [36]. At the end of each experi-
ment, tumors were excised and weighed.
For intracranial xenografts, SCID/NCR immunodeficient
mice received 5,000 viable neurosphere cells in 5 ll of cul-
ture medium by stereotactic injection to the right caudate/
putamen. In certain experiments, cells were treated with TSA
(200 nM) for 3 days or transfected with DNER expression
plasmid 48 hours prior to implantation. Cell viability was
determined by trypan blue dye exclusion. Groups of mice (n
¼ 10) were sacrificed at the indicated times and the brains
were removed for histologic studies. Tumor sizes were quanti-
fied by measuring tumor cross-sectional areas on hematoxylin
and eosin-stained cryostat sections from perfusion-fixed brains
using computer-assisted image analysis as previously
described [36]. Volumes were estimated based on the for-
mula: volume ¼ (square root of maximum cross-sectional
area)3 as previously described [36]. All animal protocols used
in this study were approved by the Johns Hopkins School of
Medicine Animal Care and Use Committee.
Immunofluorescence and Immunohistochemistry
The expression and cellular localization of CD133 (Santa
Cruz Biotechnology), GFAP, and TuJ1 were determined
by immunofluorescence. Neurosphere cells were plated
on coverslips or collected by cytospin onto glass slides. The
cells were fixed with 4% paraformaldehyde for 10 minutes
Figure 3. HDAC inhibitors induce GBM-derived neurosphere cell differentiation and apoptosis. Low passage primary neurospheres (JHH225)
and neurosphere lines (050509 and 10627) were incubated with either TSA (200 nM) or MS-275 (4 lM) for 3 days. (A, B): Neurospheres and
nonadherent cells were collected by cytospin and then stained with anti-GFAP (red) and anti-TuJ1 (green). Nuclei are stained blue. (C): Alterna-
tively, whole cell proteins were isolated and subjected to immunoblot analysis using anti-GFAP or anti-TuJ1, and anti-actin. GFAP and TuJ1
expression are induced by HDAC inhibition. Bar ¼ 20 lm. (D): Neurosphere cell viability was determined by trypan blue exclusion. (E): Neuro-
sphere cell apoptosis was determined by Annexin V flow cytometry as described in Materials and Methods. TSA increased the fraction of trypan
blue- and Annexin V-positive cells approximately two- to threefold. Data (D, E) are shown as the mean  standard error of the mean. ** p <
.01. Abbreviations: Con, control; GBM, glioblastoma; GFAP, glial fibrillary acidic protein; HDAC, histone deacetylase; TSA, trichostatin A.
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and permeabilized with PBS containing 7.5% glycine and
0.5% Triton X-100 for 30 minutes. The cells were then incu-
bated with primary antibody in staining solution (1% bovine
serum albumin [BSA] with 0.1% NP-40) for 2 hours and then
incubated with appropriate corresponding secondary antibod-
ies (fluorescein isothiocyanate [FITC]-conjugated goat anti-
mouse and Texas Red-conjugated goat anti-rabbit) for
30 minutes. Coverslips were placed with Vectashield Antifade
solution containing 40,6-diamidino-2-phenylindole (Vector
Laboratories, Burlingame, CA, http://www.vectorlabs.com).
Figure 4.
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Immunofluorescence was detected by fluorescent microscopy
using Axiovision software (Carl Zeiss, Jena, Germany, http://
www.zeiss.com).
Flow Cytometry
Flow cytometry was performed to determine the percentage
of cells expressing ALDH using the Aldefluor reagent accord-
ing to the manufacturer’s specifications (Stem Cell Technolo-
gies, Vancouver, BC, Canada, http://www.stemcell.com).
Aldefluor substrate (0.625 g/ml) was added to neurosphere
cells suspended in Aldefluor assay buffer (106 cells/ml). Cells
were then incubated for 20-30 minutes at 37C to allow the
conversion of Aldefluor substrate to its intracellular fluores-
cent product [37]. Cell fluorescence was measured using an
LSR flow cytometer equipped with 424/44 nm band pass and
670 nm long pass optical filters (Omega Optical, Brattleboro,
VT, http://www.omegafilters.com). ALDH values are pre-
sented as mean fluorescence intensity.
Flow cytometry analysis of CD133 expression was per-
formed with phycoerythrin-conjugated anti-CD133 antibody
(clone 293C3; Miltenyi Biotec, Auburn, CA, http://www.mil-
tenyibiotec.com) following the manufacturer’s protocol.
Briefly, up to 5  106 dissociated neurosphere cells were sus-
pended in 100 ll assay buffer (PBS, pH 7.2, 0.5% BSA,
2 mM EDTA) and 10 ll of the CD133 antibody were added.
The cells were gently rotated for 10 minutes in the dark at
4C, washed by adding 1 ml of assay buffer, and then pel-
leted at 300g for 10 minutes. The cell pellet was resuspended
in PBS and analyzed by a FACSCalibur fluorescence-acti-
vated cell sorting (FACS) flow cytometer (BD Biosciences,
San Jose, CA, http://www.bdbiosciences.com). Data were
quantified using CellQuest software (BD Biosciences).
Cell death was quantified using the annexin V-FITC/pro-
pidium iodide (PI) apoptosis kit (BD Bioscieneces, San
Diego, http://www.bdbiosciences.com) according to the manu-
facturer’s instructions. Briefly, dissociated cells were resus-
pended in annexin V binding buffer (150 mM NaCl, 18 mM
CaCl2, 10 mM HEPES, 5 mM KCl, 1 mM MgCl2). FITC-con-
jugated annexin V (1 lg/ml) and PI (50 lg/ml) were added to
cells, which were incubated for 30 minutes at room tempera-
ture in the dark and subjected to FACScan analysis to quan-
tify the annexin V-positive/PInegative cells.
Statistical Analysis
Data were analyzed using parametric statistics with one-way
analysis of variance. Post hoc tests included Student’s t-test
and the Tukey multiple comparison tests as appropriate using
Prizm (GraphPad Software Inc., San Diego, CA, http://
www.graphpad.com). All experiments reported here represent
at least three independent replications. All data are repre-
sented as the mean value  standard error of mean. Signifi-
cance was set at p < .05.
RESULTS
HDAC Inhibition Inhibits GBM-Derived
Neurosphere Formation
Histone modification influences the phenotype of normal stem
and progenitor cells and may play substantial roles in the ini-
tiation, growth, and malignant progression of cancer. We
examined the effect of histone deacetylase inhibition on the
growth of GBM-derived neurosphere cells under neurosphere
growth conditions. TSA and MS-275 each inhibited neuro-
sphere cell growth in a concentration- and time-dependent
manner. When neurosphere cells were treated for 72 hours,
the 50% inhibitory concentration (IC50) values for TSA and
MS-275 were 200 nM and 3.5 lM, respectively, as deter-
mined by MTS assay (supporting information Fig. 1A).
Exposing neurosphere cultures to either drug at its approxi-
mate IC50 for 144 hours inhibited neurosphere cell growth by
82%–86% (p < .001) (Fig. 1A).
TSA and MS-275 potently inhibited GBM neurosphere
cell growth in immobilized colony formation assays (Fig.
1B). Treating cultures with TSA (200 nM) continuously for
14 days inhibited the formation of colonies (100 lm diame-
ter) by 95%–98%. Pretreating cells with TSA for 3 days im-
mediately prior to initiating the assay inhibited colony forma-
tion by 88%–90%. Both TSA and MS-275 increased GBM
neurosphere cell histone acetylation three- to fivefold under
these experimental conditions, consistent with their HDAC in-
hibitory actions (supporting information Fig. 1B).
HDAC Inhibition Induces GBM-Derived
Neurosphere Cell Differentiation and Depletes
Neurospheres of Stem-Like Cells
Possible mechanisms by which HDACIs reduce GBM-derived
neurosphere cell growth and neurosphere formation include
the inhibition of neurosphere proliferation, the induction of
neurosphere cell death, the induction of neurosphere cell dif-
ferentiation, and the depletion of the stem-like cell pool in
heterogeneous neurosphere cultures. We examined the effects
Figure 4. HDAC inhibitors reduce tumor propagation by GBM-derived neurospheres and deplete tumor xenografts of neurosphere-forming
stem-like cells. (A): GBM-derived neurospheres were treated with or without TSA (200 nM) for 4 days in vitro. Equal numbers of viable cells (5
 106) were implanted s.c. to Nu/nu mice (n ¼ 10) and animals began treatment with or without TSA (0.5 mg/kg per day i.p.) 5 days after cell
implantation. The percentage of tumors formed over 8 weeks was quantified. Seventy percent of controls (buffer-treated only) formed tumors.
Transient exposure to TSA before cell implantation (in vitro) reduced tumor propagation to 30%. Tumor propagation was further inhibited by in
vivo TSA. (B): When mice bearing pre-established s.c. xenografts (50 mm3) were treated with TSA (0.5 mg/kg per day i.p.) the tumors (n ¼
6) regressed within 10 days of treatment initiation. (C): GBM-derived neurospheres were treated for 4 days with or without TSA (200 nM) in
vitro. Viable neurosphere cells (5  103) were then implanted to the caudate/putamen. After 6 weeks, the mice were sacrificed. Histological anal-
ysis revealed that tumor propagation rates by control- and TSA-treated neurosphere cells were 80% and 50%, respectively. Tumors propagated
by TSA-treated neurospheres were significantly smaller than tumors derived from control neurospheres (p < .01). (D): s.c. xenografts were estab-
lished from GBM-derived neurospheres as in (A). After 8 weeks in vivo, xenografts were dissected and equal numbers of dissociated cells were
used to establish primary cultures in neurosphere growth medium. Neurospheres formed after one passage were immobilized in agar and those
measuring >100 lm diameter were quantified by computer-assisted morphometry as described in Figure 1. All TSA treatment conditions depleted
the tumor xenografts of neurosphere-forming stem-like cells. (E): Nu/nu mice bearing GBM xenografts derived from neurosphere cells were
treated with TSA as described in (B). After 19 days of treatment, residual tumors were resected and whole tumor protein extracts were assayed
for GFAP, TuJ1, CD133, and actin by immunoblot analysis. TSA therapy in vivo decreased tumor expression of CD133 and increased tumor
expression of differentiation markers. Note that, in whole tumor protein extracts, anti-TuJ1 identified approximately three species at and below
55 kDa. Data are shown as the mean  standard error of the mean. (B–D). **p < .01 and ***p < .001, compared with controls. Abbreviations:
Con, control; GBM, glioblastoma; GFAP, glial fibrillary acidic protein; HDAC, histone deacetylase; TSA, trichostatin A.
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of HDAC inhibition on GBM neurosphere cell expression of
markers associated with the neoplastic stem-like cell pheno-
type [9, 38]. Under control neurosphere growth conditions,
ALDH was expressed by 2%–3% of neurosphere cells, as
determined by quantitative Aldefluor flow cytometry assay.
The percentage of ALDH-expressing cells diminished approx-
imately tenfold to 0.2%–0.4% when cultured for 72 hours
with either TSA or MS-275 (Fig. 2A, 2B). CD133 has been
linked to stem-like, tumor-initiating GBM cells, and nestin is
an intermediate filament protein expressed by both neuro-
sphere stem and progenitor cells. We therefore also examined
the effects of HDAC inhibition on CD133 and nestin. Flow
cytometry analysis showed that CD133 was expressed by
45% of neurosphere cells under control neurosphere growth
conditions, and the percentage of CD133þ cells dropped
approximately threefold to 15% when cultured for 72 hours
with TSA (Fig. 2C). The depletion of CD133þ cells was con-
firmed by immunofluorescence (Fig. 2D). In contrast, the
number of nestin-expressing cells was relatively preserved
following treatment with TSA (Fig. 2D).
We also examined the effects of TSA and MS-275 on
neurosphere cell expression of the astrocyte marker GFAP
and the neuronal marker b-tubulin III (TuJ1). Expression lev-
els of both differentiation markers were substantially
increased 72 hours after adding either HDACI to standard
neurosphere culture medium, as detected by immunofluores-
cence (Fig. 3A, 3B). Immunoblot analyses confirmed that
GFAP and TuJ1 protein expression increased in response to
HDAC inhibition (Fig. 3C).
HDAC inhibition also affected the viability of neuro-
sphere cells and induced neurosphere cell apoptosis. TSA
(200 nM, 72 hours) increased the fraction of injured and apo-
ptotic cells two- to threefold, as evidenced by trypan
blue staining and annexin V flow cytometry, respectively
(Fig. 3D, 3E).
HDAC Inhibition Abrogates the Tumor-Forming
Capacity of GBM-Derived Neurospheres
A defining phenotype of neoplastic stem-like cells is their
ability to propagate and maintain malignant tumors in vivo.
We and others have shown that GBM-derived neurospheres,
including the neurospheres used in this current study, form tu-
mor xenografts that recapitulate many features of human
GBM (e.g., high degree of invasiveness, necrosis) [17, 29,
39]. We examined the effect of TSA on the tumorigenicity of
GBM-derived neurosphere cells in immune-deficient mice.
s.c. xenografts were used in these initial experiments to allow
us to both assess tumor formation/growth in real time and cul-
ture primary neurospheres from resected xenografts. Animals
received equal numbers of viable (trypan blue-negative) con-
trol- or TSA-treated neurosphere cells (4  106 cells per im-
plantation site). The effect of in vivo TSA treatment was also
examined. Results are shown in Figure 4A. Control neuro-
spheres formed measurable tumors in 70% of animals. Pre-
treating neurospheres with TSA (200 nM) for 4 days prior to
cell implantation reduced tumorigenicity to 30%. Implanting
control neurosphere cells and then treating animals with TSA
(0.5 mg/kg per day i.p.) beginning on postimplantation day 3
reduced tumorigenicity to 20%. Combining in vitro and
in vivo TSA therapy generated measurable tumors in only
10% of animals. Furthermore, when mice bearing pre-estab-
lished neurosphere-derived xenografts (9 weeks postimplanta-
tion) were treated with TSA (0.5 mg/kg per day i.p.), tumors
regressed within 10 days of treatment initiation (Fig. 4B). We
asked if TSA similarly affects the growth of neurosphere-
derived orthotopic tumor xenografts. Treating GBM-derived
neurosphere cultures with TSA (200 nM) for 4 days prior to
cell implantation reduced tumorigenicity from 80% to 50%.
On postimplantation day 60, tumors that formed from TSA-
treated cells were 50% smaller than control tumors (Fig.
4C).
The reduction in tumor initiation and tumor growth rates
suggested that xenografts derived from TSA-treated cells
might be relatively depleted of their tumor-propagating stem-
like cells. TSA treatment significantly depleted tumor xeno-
grafts of cells with the capacity to generate large neurospheres
(>100 lm diameter) (Fig. 4D), and the magnitude of deple-
tion mirrored the effect of TSA on tumor initiation rates
(compare Fig. 4A with Fig. 4D). The effects of TSA on tumor
xenograft cell expression of CD133 and the differentiation
markers GFAP and TuJ1 were assessed by immunoblot analy-
sis of xenograft protein extracts. Both GFAP and TuJ1
expression increased four- to sevenfold and CD133 expression
decreased approximately two- to threefold in response to
TSA treatment (Fig. 4E). These in vivo effects parallel the
effects of HDAC inhibition on neurosphere cells observed
in vitro.
DNER Signaling Is Induced by HDAC Inhibition
and Regulates GBM-Derived Neurosphere Cell
Growth and Differentiation
The effects of HDAC inhibition on GBM-derived neurosphere
formation, differentiation, and tumor propagation led us to
use HDACIs to identify gene expression patterns that regulate
the tumor-initiating phenotype of GBM-derived neurospheres.
We examined the effect of TSA on the gene expression pro-
files of two GBM-derived neurosphere lines using Affymetrix
gene expression arrays. The expression levels of 36 genes
were found to be changed threefold of greater by TSA in both
neurosphere lines. One of these genes, DNER, was induced
five- to eightfold, as determined by quantitative RT-PCR
(supporting information Fig. 2A). Noncanonical Notch path-
way activation by DNER is mediated, in part, by the tran-
scription factor Deltex. Immunoblot and immunofluorescence
analyses showed that both DNER and Deltex-1 were induced
by TSA treatment in established GBM-derived neurosphere
lines and in low passage neurospheres derived from a human
malignant glioma (Fig. 5A–5C). Deltex-1 and DNER were
similarly induced by MS-275. We found that both TSA and
DNER directly activated noncanonical Notch signaling in
GBM-derived neurosphere cell lines, as evidenced by Deltex-
dependent induction of the myelin-related protein MAG [40,
41]. MAG expression increased 15-fold in response to TSA
and 13-fold following transfection with DNER (Fig. 5D,
5E). Neither TSA nor DNER transfection induced expression
of the canonical Mastermind-dependent, Deltex-independent
Notch pathway target Hes1 (supporting information Fig. 3A,
3B) [42]. siRNA-mediated Deltex expression knockdown
(supporting information Fig. 2D) inhibited MAG induction by
both TSA and DNER (Fig. 5D, 5E, using SiDeltex-1.1; sup-
porting information Fig. 3C, 3D, using another siRNA, SiDe-
ltex-1.2). Taken together, these findings indicate that HDAC
inhibition activates a noncanonical DNER/Deltex signaling
pathway in GBM-derived neurospheres.
We used a gene expression knockdown approach to deter-
mine if DNER mediates the GBM neurosphere response to
HDAC inhibition. Transient transfection of GBM neuro-
spheres with anti-DNER siRNA (SiDNER) potently inhibited
the low level of basal DNER expression and also inhibited
DNER induction in response to TSA (supporting information
Fig. 2B, 2C). We asked if SiDNER altered neurosphere
growth inhibition following HDAC inhibition. GBM neurosphere
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cells were treated with TSA (200 nM, 72 hours) with or without
SiDNER (50 nM, 48 hours). The cells were then transferred to
standard neurosphere growth medium for 7 days. Results are
shown in Figure 6A. Neurosphere formation was inhibited by
TSA and not affected by SiDNER alone. However, cells treated
with both TSA and SiDNER formed threefold more neuro-
spheres than cells treated with TSA and control siRNA. Thus,
preventing DNER induction with SiDNER partially blocked the
growth inhibitory effects of TSA.
DNER was found to induce the differentiation of GBM
neurosphere cells as assessed by GFAP and TuJ1 expression
(Fig. 6B, 6D). GFAP and TuJ1 expression levels increased
approximately threefold and approximately fourfold, respec-
tively, as determined by immunoblot analysis. Forced expres-
sion of DNER in neurosphere cells reduced their proportion
of CD133þ cells by 50% (Fig. 6C). Mirroring the ability of
SiDNER to reverse the inhibitory effect of TSA on neuro-
sphere cell colony formation, SiDNER was also found to
Figure 5. HDAC inhibition induces DNER and Deltex-1 protein expression in GBM-derived neurospheres. Low passage primary neurospheres
(JHH225) and neurosphere lines (20913 and 10627) were treated with or without TSA (200 nM) for 4 days. (A): Equal amounts of total cell pro-
tein were assayed for DNER, Deltex-1, and GAPDH by immunoblot analysis. (B, C): Control- and TSA-treated neurospheres were collected by
cytospin and subjected to anti-DNER (green) and anti-Deltex-1 (red) immunofluorescence. Nuclei are stained blue. Bar ¼ 20 lm. (D): GBM-
derived neurosphere cells (10627) were incubated with or without TSA for 72 hours. Eight hours after adding TSA, cells were treated with or
without SiDeltex-1.1 (30 nM) for a total of 64 hours. MAG mRNA was then quantified by real-time reverse transcription-polymerase chain reac-
tion. TSA induced MAG expression 15-fold and SiDeltex-1 inhibited MAG induction. (E): GBM-derived neurosphere cells were transfected
with full-length DNER cDNA with or without SiDeltex-1.1. Seventy-two hours later, MAG mRNA levels were determined as described in (D).
MAG expression increased 13-fold in response to DNER. SiDeltex-1 inhibited MAG induction by DNER. **p < .01. Similar responses to Del-
tex-1 expression knockdown were obtained using a second Deltex-targeting sequence, SiDeltex-1.2 (see supporting information Fig. 4D, 4E).
Abbreviations: Con, control; DNER, Delta/Notch-like epidermal growth factor-related receptor; GAPDH, glyceraldehyde-3-phosphate dehydro-
genase; GBM, glioblastoma; HDAC, histone deacetylase; TSA, trichostatin A.
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reverse TSA-induced neurosphere cell differentiation, as
determined by GFAP and TuJ1 immunofluorescence (Fig. 6D,
using SiDNER.1, and supporting information Fig. 4, using
another siRNA, SiDNER.2). Conversely, transfecting neuro-
sphere cells with DNER cDNA induced GFAP and TuJ1
expression, mimicking the response to TSA treatment (Fig.
6D). In contrast to its effects on neurosphere cell differentia-
tion, DNER had no detectable effect on neurosphere cell via-
bility or apoptosis. SiDNER did not alter the viability of con-
trol- or TSA-treated neurosphere cells (Fig. 6E). Forced
Figure 6.
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DNER expression did not alter the viability or annexin V
staining of neurosphere cells (Fig. 6F). Together, these loss-
and gain-of function results strongly suggest that DNER sig-
naling pathways modulate GBM stem-like cell growth, differ-
entiation, and possibly tumor propagation and maintenance.
Finally, we examined the effect of DNER upregulation on
the growth of orthotopic tumor xenografts derived from GBM
neurospheres. Mice received equal numbers of viable GBM
neurosphere cells by stereotaxic injection to the caudate/puta-
men 72 hours after the cells were transfected with control or
full-length DNER plasmid expression vectors. Tumor volumes
assessed on postimplantation day 68 showed that tumor xeno-
grafts derived from DNER-transfected cells were 60%
smaller than controls (Fig. 7).
DISCUSSION
Glioblastoma multiforme is the most common and aggressive
of the primary brain cancers. Despite dramatic reductions in
tumor burden with surgery, radiotherapy, and chemotherapy,
tumor recurrence is almost universal [43]. The high frequency
of GBM recurrence reflects the inherent chemo-/radiation re-
sistance of at least a subset of the invasive cancer cells that
inevitably remain after aggressive surgery. According to the
cancer stem-cell hypothesis, only a small number or, at its
extreme interpretation, a single remaining tumor cell with
stem-like properties can ultimately result in the recurrence of
a heterogeneous GBM. There has been considerable progress
in identifying the biological and molecular features of GBM
cell subpopulations with stem-like properties since they were
isolated using neurosphere growth conditions and shown to
efficiently propagate tumor xenografts contemporaneously in
2004 by Singh et al. [3] and Galli et al. [10]. Perhaps the
most clinically relevant features of GBM-derived stem-like
cells identified to date are their ability to efficiently form tu-
mor xenografts with the complex histologic features of human
GBM and their inherent resistance to chemotherapy and radia-
tion therapy. The resistance of neoplastic stem-like cells to
DNA-damaging agents has been attributed in part to Chk1/2-
dependent DNA repair mechanisms in GBM-derived cells
[14] and to Wnt/b-catenin signaling in breast cancer-derived
cells [44]. Neurodevelopmental pathways regulate GBM-
derived stem-like cells. Among these are the Hh and canoni-
cal Notch/Mastermind pathways, found to maintain the cancer
stem-cell phenotype, and bone morphogenetic proteins, which
induce their differentiation and inhibit their tumor-initiating
potential [17, 29, 39, 45]. Effort is under way to translate
these discoveries to reduce the tumor-initiating potential of
the stem-like cell subpopulation through either differentiation
and/or chemo-/radiation sensitization in conjunction with con-
ventional treatments.
We now show that histone deacetylase inhibition induces
GBM-derived stem-like cells to differentiate, undergo apopto-
sis, and loose their capacity to both grow as neurospheres and
initiate tumor xenografts. These cell responses mimic, to
some degree, the responses of normal neural stem/progenitor
cells to HDAC inhibition [20, 26, 46], supporting the current
concepts regarding shared regulatory mechanisms and possi-
bly overlapping origins between normal neural and GBM-
derived neoplastic stem cells. Our results are interesting in
the context of the recent findings of Lee et al. [17], showing
that epigenetic gene regulation via promoter methylation can
alter the differentiation and tumor-initiating capacity of GBM
stem-like cells. The HDACIs used in our experiments, MS-
275 (now available as Sndx-275; Syndax Pharmaceuticals,
Waltham, MAhttp://www.syndax.com) and TSA, also have
antitumor activity against tumor xenograft models derived
from cancer cells maintained under traditional serum-contain-
ing culture conditions [47, 48]. HDAC inhibition can broadly
induce tumor suppressors and inhibit tumor promoters regard-
less of cell stemness. It is also possible that the antitumor
effects of HDACIs in traditional xenograft models reflect, at
least in part, the targeting of tumor-initiating cell subpopula-
tions with stem-like characteristics within traditional cancer
cell lines [49, 50]. HDACIs, including Sndx-275 and suberoy-
lanilide hydroxamic acid, are currently in clinical trials for
solid malignancies. Our findings expand the influences of
HDACIs to GBM stem-like cells and the nonclassical Notch
ligand DNER. The ability of HDACIs to cross the blood–
brain barrier makes them applicable to clinical testing in brain
tumor patients [51].
Our conclusions that HDAC inhibition and DNER, an
HDACI-induced gene product, differentiate GBM stem-like
cells and inhibit their tumor-initiating phenotype are based on
complementary biological and molecular endpoints. In con-
trast to hematopoietic neoplastic stem cells, cell surface
markers that reliably identify tumor-initiating stem cells in
solid cancers are lacking. Therefore, our approach emphasized
experimental endpoints that are well accepted to consistently
associate with the neoplastic stem-like phenotype, namely, the
formation of large neurospheres in vitro and tumor xenograft
initiation by neurosphere-derived cells. CD133 and ALDH,
markers that correlate with neoplastic neurosphere growth and
Figure 6. DNER regulates GBM-derived neurosphere cell growth and differentiation and not apoptosis. (A): Neurospheres (line 10627) were
dissociated, transfected with control siRNA (SiCon) or with anti-DNER siRNA (SiDNER), and replated in neurosphere growth medium with or
without TSA (200 nM) as shown. Seven days later, neurospheres were immobilized in soft agar and those measuring >100 lm diameter per low
powered field were quantified by computer-assisted morphometry. Cultures treated with TSA plus SiDNER contained threefold more large neuro-
spheres than cultures treated with TSA alone. DNER expression inhibition rescues neurosphere cells from the growth-inhibiting effects of TSA.
(B): Neurosphere cells were transfected with control plasmid or with plasmid containing full-length DNER cDNA. Sixty hours later, total cell
lysates were assayed for GFAP, TuJ1, and actin by immunoblot analysis. Transgenic DNER induces both GFAP and TuJ1 expression. (C): Neu-
rosphere cells were transfected with control plasmid or with DNER as in (B). Forty-eight hours later, neurospheres and nonadherent cells were
collected, dissociated, and subjected to flow cytometry for CD133. DNER expression reduces the fraction of CD133þ cells. (D): Neurosphere
cells were transfected with TSA with or without SiDNER or transfected with full-length DNER cDNA and then grown under neurosphere growth
conditions for 7 days. Nonadherent cells and neurospheres were then collected by cytospin and stained for the differentiation markers GFAP and
TuJ1. DNER expression inhibition reversed TSA-induced differentiation and expressing full-length DNER induced differentiation. (E): GBM-
derived neurospheres (line 10627) were dissociated, transfected with control siRNA (SiCon) or with anti-DNER siRNA (SiDNER), and replated
in neurosphere growth medium with or without TSA (200 nM) as shown. Sixty hours later, neurosphere cell viability was determined by trypan
blue exclusion. SiDNER did not alter the fraction of trypan blue-positive cells in either control- or TSA-treated neurospheres. (F): Neurosphere
cells were transfected with control plasmid or with plasmid containing full-length DNER cDNA. Sixty hours later, cell viability was determined
by trypan blue staining and apoptosis was determined by annexin V flow cytometry. Forced DNER expression had no effect on either parameter
of cell viability. Data are shown as the mean  standard error of the mean (A, C). Bar, 20 lm; *p < .05; **p < .01; NS, p > .05. Abbrevia-
tions: Con, control; DNER, Delta/Notch-like epidermal growth factor-related receptor; GAPDH, glyceraldehyde-3-phosphate dehydrogenase;
GBM, glioblastoma; GFAP, glial fibrillary acidic protein; siRNA, small interfering RNA; TSA, trichostatin A.
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tumor initiation, were also examined and found to be consis-
tently lost, whereas the neuronal and glial differentiation
markers TuJ1 and GFAP were consistently induced in
response to HDAC inhibition and DNER expression. That
similar results were obtained using (a) multiple human GBM-
derived neurosphere lines and low passage neurosphere cul-
tures established at different institutions, (b) in vitro and in
vivo model systems, (c) two chemically distinct HDACIs, and
(d) both DNER gain and loss of function renders confidence
in their broad applicability to cellular models in vitro and
more biologically complex tumors in vivo.
The effects of HDAC inhibition can be broad and not lim-
ited to proliferation inhibition and differentiation. Consistent
with this is our finding that HDAC inhibition also induced
GBM neurosphere cell death via a predominantly apoptotic
mechanism. In contrast to its effects on cell differentiation,
the HDAC-induced gene product DNER had no apparent
effects of neurosphere cell viability. We are currently explor-
ing in more detail the transcriptional events downstream of
HDAC inhibition specifically responsible for GBM neuro-
sphere cell death. Understanding the molecular determinants
that control whether GBM neurosphere cells die or differenti-
ate will likely translate to more effective strategies for target-
ing neoplastic stem-like cells.
We used the effects of HDAC inhibition on gene expres-
sion to identify specific gene products that potentially regulate
the GBM stem-like cell phenotype. We show, for the first
time, that DNER functions as a tumor suppressor and differ-
entiating factor in GBM-derived neurosphere cells. DNER is
a single-pass transmembrane Notch ligand containing 10
extracellular EGF-like repeats and lacking the Delta, Serrate,
Lag-2 (DSL) Notch-binding motif that characterizes classical
Notch ligands [52]. DNER is strongly expressed by cerebellar
Purkinje cells and regulates cerebellar development and neu-
rodevelopmental interactions between Purkinje cells and Berg-
mann glia that express Notch. Notch ligands induce Notch re-
ceptor cleavage by metalloprotease and c-secretase releasing
the Notch intracellular domain (NICD) that transduces to ca-
nonical (CSL/NICD/Mastermind transcriptional complex) and
noncanonical (NF-jB/NICD and CSL/NICD/Deltex transcrip-
tional complex) pathways. Signaling through the classical
Notch pathway has multiple contextual functions, such as
stem cell self-renewal, progenitor cell fate determination, and
terminal differentiation of proliferating cells [53–55]. DNER
promotes Bergmann glial process formation in vitro via a Del-
tex-dependent mechanism. Our findings that Deltex-1 is
induced along with DNER by HDAC inhibition and that
DNER induces expression of the Deltex target gene MAG
support a role for a noncanonical signaling mechanism.
A complex role for Notch signaling in central nervous
system malignancies is emerging. High-grade gliomas express
the DSL-containing Notch ligand Jagged, Notch receptors,
and downstream target genes induced by CSL/NICD/Master-
mind in patterns that have been found to correlate with malig-
nant grade and poor prognosis [56, 57]. Fan et al. [45] found
that inhibiting canonical Notch signaling with c-secretase
inhibitors can deplete embryonal brain tumor cell lines of
their neoplastic stem-like cells and tumor-initiating capacity.
These findings support an oncogenic role for classical Notch
signaling in certain brain tumor subtypes and contrast the tumor
suppressive effects of DNER reported here in GBM-derived
neurospheres. Developing a detailed framework for the onco-
genic and tumor-suppressing effects of canonical and nonca-
nonical Notch signaling in brain cancer stem-like cells will
require a more complete understanding of the cell type- and
context-dependent actions and interactions of the numerous
Notch ligands, Notch receptors, and their downstream effectors.
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Figure 7. Transgenic DNER inhibits the growth of orthotropic tu-
mor xenografts derived from GBM neurospheres. GBM-derived neu-
rosphere cells (10627) were transfected with full-length DNER cDNA
(or control plasmid). Twenty-four hours later, cells were dissociated
and implanted to the right striatum of SCID/beige mice (5  103 via-
ble cells/animal). (A): Animals were sacrificed 64 days later and
tumors were identified in brain sections stained with hematoxylin &
eosin. Bar ¼ 100 lm. (B): Tumors derived from DNER-transfected
cells were significantly smaller than controls. Data are shown as the
mean  standard error of the mean. *p < .05. Abbreviations: Con,
control; DNER, Delta/Notch-like epidermal growth factor-related re-
ceptor; GBM, glioblastoma.
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